mk-0616
merck
[]
dr. ballantyne discussing findings from phase 2b, randomized, double-blind, placebo-controlled, multi-center trial showing significant decrease in ldl with oral pcsk9 inhibitor mk-0616 compared to placebo see full article in below 
Current cardiology fellow & future AHFTC fellow, food lover, singer, a sailor in my dreams @cardionerds #FIT #WIC #ChooseCardiology @OHSUcardio @wellesleyalums